Ensysce Biosciences, Inc.

Greetings and welcome to the Ensysce Biosciences, Inc. Corporate Update Call. At this time, all participants are in a listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. It is now my pleasure to introduce your host, Dr. Lynn Kirkpatrick, Chief Executive Officer. Thank you. You may begin.

Thank you, Operator. And good morning, everyone. Thank you for joining us. We recently issued a press release outlining our acquisition of SciBioPharma and a concurrent private placement financing. That release, along with an updated corporate presentation, is available at www.Ensysce.com under the Investors section. Before we begin, I would like to remind everyone that statements made during this call that are not historical facts including statements relating to NCIS's expected future performance, future business prospects and future events or plans and the anticipated benefits of the transaction may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject of the safe harbor protection provided by the Reform Act. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from those forecast due to the impact of many factors beyond the control of Ensysce. Ensysce undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. except as required by law. Participants are directed to the risk factors set forth in NCISIS filings and the Security and Exchange Commission, including in its most recent Form 10-K and Form 10-Q and in other filings that it makes with the U.S. Securities and Exchange Commission. During the call today, I will review the details of our acquisition of SciBioPharma and the concurrent private placement financing. James Morrison, founder and chief executive officer of SciBioPharma, who has joined NCIS as president, and Professor Richard Langford, SciBioPharma's chief medical officer, will then provide an overview of their lead program side 200 for the treatment of complex regional pain syndrome or CRPS. I'd like to start by describing how this transaction developed. Our board of directors undertook a thorough evaluation of strategic alternatives with a focus on maximizing value for NCISIS shareholders. After a robust process, the board concluded that this acquisition represented the most significant value creation opportunity evaluated, including the synergies between the two companies. The clinical data supporting SCI 200 and SCI Biopharma's approach to treating the devastating condition of CRPS reinforced our conviction to this program. In addition to the acquisition, We also announced financings of up to $77 million that included a private placement of $21.5 million through the sales of Series C non-voting convertible preferred stock to a group of institutional investors, $17.1 million of SciBio farmers' cash and cash equivalents from a pre-acquisition convertible note financing, and up to another 38.6 million upon achievement of a clinical trial milestone. The financing was led by Ally Bridge Group and included participation from Perceptive Advisors, Delora Investments, Iterion Capital, and Adage Capital Partners, LP. The proceeds from these finances are intended to be used primarily to advance PSY 200 through key clinical milestones including top line data from a randomized phase two trial assessing efficacy, safety, and tolerability in participants with CRPS type one and to prepare the program for registrational development. Cy200 is a botanical psilocybin extract designed to provide a neural reset for CRPS. It has already received US FDA orphan drug designation for the treatment of CRPS which we believe provides important regulatory and commercial advantages as we advance the program. I want to emphasize that the private placement was intentionally sized to support the immediate strategic objectives of executing the Phase II trial of PSI 200 while maintaining financial discipline. and, importantly, this transaction is not expected to come at the expense of our existing pipeline. We will continue to progress PF614 and PF614-MFAR, which we believe represents a fundamentally new approach to opioid safety. It's now my pleasure to introduce James Morrison, Founder and Chief Executive Officer of Psi Biopharma, who joins NCIS as President and has also joined our board of directors. James led SCI Biopharma since its founding, building the company's clinical strategy for SCI 200 from early discovery to orphan drug designation and into phase two development. James, over to you.

Thank you, Lynn, and good morning, everyone. I would like to echo Lynn's thanks to those joining us this morning and to the investors supporting the recent financings. We at SciBioPharma are excited to join NCISE with the opportunity to deploy this capital toward developing serotonin receptor agonist therapeutics beyond mood disorders, starting with a much needed meaningful treatment for patients suffering from an orphan condition, complex regional pain syndrome. Professor Richard Langford, our CMO, and I will take a few minutes to walk through why we believe CRPS represents such a significant unmet need and why the neuroplastigenic effect of our lead candidate PSY200 is well positioned to address this. Richard.